Abstract
Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Current HIV Research
Title: Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression
Volume: 7 Issue: 4
Author(s): Carelia Garcia-Moruja, Patricia Rueda, Carmen Torres, Jose Alcami, Francisco Luque and Antonio Caruz
Affiliation:
Keywords: CXCL12, mRNA stability, AIDS, rs1801157, UTR
Abstract: Objective: To investigate the molecular phenotype of the AIDS-onset delaying polymorphism in CXCL12β 3UTR (rs1801157). Methods: The 3UTRs of the CXCL12β isoform containing the A or G polymorphic variants were cloned downstream of the Luciferase gene under the control of the CXCL12 promoter. The plasmids were transfected in U373 and LC5 cells and the polymorphism phenotype was evaluated in terms of Luciferase activity and mRNA stability. Results: The 3A genotype compared to 3G leads to an increased luciferase activity in unstimulated and PMA+Ionomycin treated cells both in astrocytes (p= 0,0002, p = 0,02) and fibroblasts (p = 0,002, p = 0,03). The mRNA containing the 3A variant have two-fold longer half-life compared to the 3G variant (p = 6,99E-7). Conclusions: CXCL12β 3A polymorphism, previously associated with resistance to AIDS progression and other diseases, leads to increased levels of CXCL12 mRNA, the results presented here demonstrate that this effect is a consequence of an enhanced mRNA stability. Our data contribute to characterize the CXCL12 as a potential pharmacological target in AIDS, autoimmune diseases and cancer.
Export Options
About this article
Cite this article as:
Garcia-Moruja Carelia, Rueda Patricia, Torres Carmen, Alcami Jose, Luque Francisco and Caruz Antonio, Molecular Phenotype of CXCL12β 3UTR G801A Polymorphism (rs1801157) Associated to HIV-1 Disease Progression, Current HIV Research 2009; 7 (4) . https://dx.doi.org/10.2174/157016209788680543
DOI https://dx.doi.org/10.2174/157016209788680543 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
Call for Papers in Thematic Issues
Management of HIV: Management of HIV: old challenges and new needs
The aim of this thematic issue is to provide the most recent updates regarding the effective management of HIV infection. Antiretroviral therapy (ART) has significantly decreased HIV-related mortality, leading to an enhancement in the quality of life and life expectancy for people living with HIV (PLWH). Despite the numerous advancements ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Crystallization and Preliminary X-Ray Studies of the Fab Fragment from a Humanized Version of the Mouse Anti-Human Fas Antibody Hfe7a
Protein & Peptide Letters Vitamin D : Autoimmunity and Gender
Current Medicinal Chemistry The Unique Inhibitory IgG Receptor--FcγRIIb
Protein & Peptide Letters Cytokines and their Antagonists as Therapeutic Agents
Current Medicinal Chemistry Expression and Function of Cytokines and Chemokines in Neuropsychiatric Related Systemic Lupus Erythematosus
Current Rheumatology Reviews Cytokines in Systemic Lupus Erythematosus
Current Molecular Medicine Ubiquitin Ligases as Key Elements for the Modulation of the Immune Response: An Insight in the Pathogenesis of Autoimmunity
Current Rheumatology Reviews NF-κB, a Potential Therapeutic Target for the Treatment of Multiple Sclerosis
CNS & Neurological Disorders - Drug Targets SAGE Application in Hematological Research
Current Pharmaceutical Biotechnology Recent Trials for FTY720 (Fingolimod): A New Generation of Immunomodulators Structurally Similar to Sphingosine
Reviews on Recent Clinical Trials Role of the α7 Nicotinic Acetylcholine Receptor and RIC-3 in the Cholinergic Anti-inflammatory Pathway
Central Nervous System Agents in Medicinal Chemistry Epigenetic Regulation of Regulatory T Cells in Kidney Disease and Transplantation
Current Gene Therapy Clinical Applications of Autoimmunity to Citrullinated Proteins in Rheumatoid Arthritis, from Improving Diagnostics to Future Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Basement Membrane Peptides: Functional Considerations and Biomedical Applications in Autoimmunity
Current Medicinal Chemistry Conjugates of Cell Adhesion Peptides for Therapeutics and Diagnostics Against Cancer and Autoimmune Diseases
Current Topics in Medicinal Chemistry Chaperonopathies and Chaperonotherapy. Hsp60 as Therapeutic Target in Cancer: Potential Benefits and Risks
Current Pharmaceutical Design Purine Nucleoside Analogs as Immunosuppressive and Antineoplastic Agents: Mechanism of Action and Clinical Activity
Current Medicinal Chemistry New Insights on the Possible Role of Mast Cells in Aspirin-Induced Asthma
Current Molecular Pharmacology Editorial: Current Strategies for Drug Discovery Targeting Neurological Autoimmune Diseases
Central Nervous System Agents in Medicinal Chemistry Development of Bruton’s Tyrosine Kinase Inhibitors for Rheumatoid Arthritis
Current Medicinal Chemistry